EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

Keith W Pratz iD, Brian A Jonas iD, Vinod Pullarkat iD, Michael J Thirman, Jacqueline S Garcia iD, Hartmut Döhner, Christian Récher iD, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang iD, Sung-Soo Yoon, Ofir Wolach und 15 weitere

American Journal of Hematology · 2024-04 · 99 (4) · 615-624

DOI: 10.1002/ajh.27246 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, online erschienen am 11.02.2024. Verfasst von Keith W Pratz und 26 weiteren Autor:innen. Beteiligte Einrichtung: Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neutropenia, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 258-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie, Genentech, AbbVie Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax‐azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE‐A study (NCT02993523). Here, long‐term follow‐up is presented to address survival benefit and long‐term outcomes with venetoclax‐azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax‐azacitidine or placebo‐azacitidine. OS was the primary endpoint; complete remission with/without blood count recovery (CR/CRi) was a key secondary endpoint. This final analysis was conducted when 100% of the predefined 360 OS events occurred. In VIALE‐A, 431 patients were enrolled to venetoclax‐azacitidine ( n = 286) or placebo‐azacitidine ( n = 145). At 43.2 months median follow‐up, median OS was 14.7 months (95% confidence interval [CI], 12.1–18.7) with venetoclax‐azacitidine, and 9.6 months (95% CI, 7.4–12.7) with placebo‐azacitidine (hazard ratio, 0.58 [95% CI, 0.47–0.72], p < .001); the estimated 24‐month OS rate was 37.5% and 16.9%, respectively. Median OS for patients with IDH1/2 mutations and those with measurable residual disease responses was reached in this final analysis. CR/CRi rate was similar to interim analysis. Any‐grade hematologic and gastrointestinal adverse events were most common in venetoclax‐azacitidine and placebo‐azacitidine arms, including thrombocytopenia (47% and 42%) and neutropenia (43% and 29%). No new safety signals were identified. Long‐term efficacy and safety confirm venetoclax‐azacitidine is an improvement in standard‐of‐care for patients with AML who are not eligible for intensive chemotherapy because of advanced age or comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteNeutropeniaSulfonamidesBridged Bicyclo Compounds, HeterocyclicHumansFollow-Up StudiesAzacitidineAntineoplastic Combined Chemotherapy Protocols

Substanzen

venetoclaxAzacitidineSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Internal Medicine, Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, California, USA.
  • Department of Hematology and Hematopoietic Cell transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
  • Section of Hematology and Oncology, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.

ORCID-Profile: Keith W Pratz, Brian A Jonas, Vinod Pullarkat, Jacqueline S Garcia, Christian Récher, Jianxiang Wang, Brenda Chyla, Courtney D DiNardo

Förderung

  • AbbVie
  • Genentech
  • AbbVie Canada
  • Genentech Foundation

Zitieren

APA

Pratz, K. W., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Döhner, H., Récher, C., Fiedler, W., Yamamoto, K., Wang, J., Yoon, S. S., Wolach, O., Yeh, S. P., Leber, B., Esteve, J., Mayer, J., Porkka, K., Illés, Á., Lemoli, R. M., …, & DiNardo, C. D. (2024). Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia. American Journal of Hematology, 99(4), 615-624. https://doi.org/10.1002/ajh.27246

Vancouver

Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, et al. Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia. American Journal of Hematology. 2024;99(4):615-624. doi:10.1002/ajh.27246

BibTeX
@article{Pratz2024,
  author = {Pratz, Keith W and Jonas, Brian A and Pullarkat, Vinod and Thirman, Michael J and Garcia, Jacqueline S and Döhner, Hartmut and Récher, Christian and Fiedler, Walter and Yamamoto, Kazuhito and Wang, Jianxiang and Yoon, Sung-Soo and Wolach, Ofir and Yeh, Su-Peng and Leber, Brian and Esteve, Jordi and Mayer, Jiri and Porkka, Kimmo and Illés, Árpád and Lemoli, Roberto M and Turgut, Mehmet and Ku, Grace and Miller, Catherine and Zhou, Ying and Zhang, Meng and Chyla, Brenda and Potluri, Jalaja and DiNardo, Courtney D},
  title = {Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {4},
  pages = {615--624},
  doi = {10.1002/ajh.27246}
}
Kostenlos starten →